Home Compare AU vs ZEAL.CO
Stock Comparison · Structural lead, mixed market

AngloGold Ashanti vs Zealand Pharma A/S: Which Stock Looks Stronger in 2026?

Zealand Pharma A/S holds the cleaner structural position, with growth as the main driver and profitability adding further support. AngloGold Ashanti does not offset that deficit through any equally strong structural edge elsewhere. In the market, AngloGold Ashanti carries the stronger setup — intact trend against Zealand Pharma A/S's broken trend. That leaves a split case: the structural lead stays with Zealand Pharma A/S, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (AU: Russell 1000, ZEAL.CO: STOXX 600).

Updated 2026-05-17

The lead is spread across growth and profitability, rather than sitting in one isolated gap. The overall score gap is 18 points in favour of Zealand Pharma A/S.

Trajectory Similarity
0.65
Moderately similar
Peer-set rank: #5
within AngloGold Ashanti plc's functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

The pair shares a valid long-term profile match, but the trajectories are not especially close.

The match is driven mainly by investment intensity and operating margin level.

Similarity drivers
investment intensityoperating margin level
What reduces the match
recent revenue growth
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
AU
AngloGold Ashanti plc
65
Peer-Score
Signal qualitylow
Peer basis: Russell 1000
vs
ZEAL.CO
Zealand Pharma A/S
83
Peer-Score
Signal qualitylow
Peer basis: STOXX 600

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: AU vs ZEAL.CO Profitability 76 100 Stability 37 36 Valuation 84 88 Growth 50 94 AU ZEAL.CO
Gap Ranking
#1 Growth +44
#2 Profitability +24
#3 Valuation +4
#4 Stability +1
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for AU and ZEAL.CO Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer AUZEAL.CO Relative valuation Structural strength

Zealand Pharma A/S looks stronger both structurally and on relative valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Both profiles are strong on growth, but Zealand Pharma A/S leads clearly.
Profitability
On profitability, the same pattern holds: both rank well, but Zealand Pharma A/S still sits higher.
Growth — Dominant Gap
AU
50
ZEAL.CO
94
Gap+44in favour of ZEAL.CO

Growth adds another layer to the lead, with a very wide gap in revenue growth between the two companies.

What keeps the gap from being one-sided

On the market side, AngloGold Ashanti carries the stronger trend while Zealand Pharma A/S's trend has broken — the market setup does not confirm the structural advantage.

What this means for the comparison

Growth is the clearest driver, and profitability also supports Zealand Pharma A/S's broader structural position.

Explore full peer positioning in AssetNext

Break down the AU vs ZEAL.CO comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-and-profitability comparisons

Explore how AU and ZEAL.CO each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.